HER2+ Breast Cancer

Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.

The European Union has approved trastuzumab deruxtecan for patients with previously treated, HER2-positive metastatic solid tumors.

Milana V. Dolezal, MD, MSci, notes how the CLEOPATRA trial paved the way for further breast cancer research and highlighted data from DESTINY-Breast09.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

The FDA has approved palbociclib plus trastuzumab, with/without pertuzumab, and ET as maintenance in HR+, HER2+ metastatic breast cancer.

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

Breast cancer data from ASCO 2026 confirm the clinical benefits of several investigational treatment approaches across disease subtypes.

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.

The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.

Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.

Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

Read a refresh of the top FDA news in breast cancer from April 2026, including an ODAC decision and a breakthrough device designation.

Sara M. Tolaney, MD, MPH, discusses how the early-stage HER2-positive breast cancer treatment paradigm is evolving with the emergence of new phase 3 data.

Sara M. Tolaney, MD, MPH, discusses how therapeutic strategies are evolving within the HER2-positive breast cancer treatment paradigm.

During a recent Peer Exchange, breast and lung cancer experts discussed comprehensive strategies for identifying and mitigating the AEs associated with ADCs.

The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.